Vertex to acquire Crinetics for $85 per share in cash; CRNX surges
Jul 6, 2026, 4:51 PM EDT3 sourcesAI-analyzed
Why it may matterVerify against the original reporting
The cash offer establishes an explicit value floor near $85, triggering a strong immediate uptick in CRNX. Historical takeovers show target stocks often move toward the offer price, though closing risk remains if regulatory or financing issues arise.
AI summary
What happened, with direct paths to the underlying reporting
Vertex has agreed to acquire Crinetics for $85 per share in cash, valuing the company at about $10 billion. The deal, unanimously approved by boards, is expected to close in Q3. Crinetics' stock jumped more than 100% in after-hours trading to roughly $84.70, signaling strong near-term investor acceptance but leaving execution risk until closing.
Vertex to buy Crinetics for $85 per share in cash.
Equity value around $10B; closing expected in Q3.
Crinetics shares up ~101% after-hours; price near $84.69.
Transaction unanimously approved by boards.
How to read this signal
Transparent limits for an AI-generated research aid
StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.
Related signals
More source-backed signals connected by company or event
Vertex Pharmaceuticals announced it will acquire Crinetics Pharmaceuticals for about $10 billion in equity value, a deal that would pair Crinetics' oncology pipeline with Vertex's…
Representative Gottheimer disclosed a September 25 investment in CRNX. CRNX stock rose 11.66% since Gottheimer's purchase at $50.58. Analysts unanimously rate CRNX as 'Buy', with…
- CRNX reported a quarterly loss of $0.93 per share, missing estimates. - Revenue for CRNX was $0.64 million, missing estimates by 21.47%. - CRNX shares have gained 43% this year,…